Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP13 | P45452 | 19/20 | 0.62 |
| ▸ | MMP1 | P03956 | 18/20 | 0.62 |
| ▸ | USP2 | O75604 | 1/20 | 0.55 |
| ▸ | HTT | P42858 | 1/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.55 |
| ▸ | MMP2 | P08253 | 3/20 | 0.48 |
| ▸ | MMP14 | P50281 | 2/20 | 0.48 |
| ▸ | MMP3 | P08254 | 1/20 | 0.48 |
| ▸ | MMP9 | P14780 | 1/20 | 0.48 |
| ▸ | MMP8 | P22894 | 1/20 | 0.48 |
| ▸ | MMP12 | P39900 | 1/20 | 0.48 |
| ▸ | ADAMTS4 | O75173 | 1/20 | 0.48 |
| ▸ | MEP1B | Q16820 | 1/20 | 0.48 |
| ▸ | ADAMTS5 | Q9UNA0 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6869740 | 0.88 | MMP1 (0.77) | MMP13MMP1USP2HTTSMN1; SMN2 | |
| SCHEMBL5675304 | 0.87 | USP2 (0.60) | MMP13MMP1USP2HTTSMN1; SMN2 | |
| SCHEMBL14676227 | 0.85 | USP2 (0.58) | MMP13MMP1USP2HTTSMN1; SMN2 | |
| SCHEMBL5674362 | 0.85 | USP2 (0.56) | MMP13MMP1USP2HTTSMN1; SMN2 | |
| SCHEMBL7066967 | 0.85 | HTT (0.59) | MMP13MMP1USP2HTTSMN1; SMN2 | |
| SCHEMBL6964392 | 0.83 | MMP1 (0.56) | MMP13MMP1USP2HTTSMN1; SMN2 | |
| SCHEMBL14675849 | 0.82 | USP2 (0.55) | MMP13MMP1USP2HTTSMN1; SMN2 | |
| SCHEMBL27415619 | 0.82 | MMP1 (0.76) | MMP13MMP1USP2HTTSMN1; SMN2 | |
| SCHEMBL27450137 | 0.82 | MMP1 (0.65) | MMP13MMP1USP2HTTSMN1; SMN2 | |
| SCHEMBL7064055 | 0.81 | USP2 (0.62) | MMP13MMP1USP2HTTSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1222176-A1 | AMINO LACTAM SULFONAMIDES AS INHIBITORS OF A$g(b) PROTEIN PRODUCTION | Bristol-Myers Squibb Pharma Company (US) | 2002-07-17 | — | — | EP | claimed |
| WO-2001027091-A1 | AMINO LACTAM SULFONAMIDES AS INHIBITORS OF Aβ PROTEIN PRODUCTION | DU PONT PHARMACEUTICALS COMPANY (US) | 2001-04-19 | — | — | WO | claimed |
| US-20030130251-A1 | Amino lactam sulfonamides as inhibitors of A-beta protein production | THOMPSON LORIN A (US) | 2003-07-10 | — | — | US | disclosed |
| US-6503901-B1 | Alzheimer*s disease and Down*s syndrome treatment | BRISTOL MYERS SQUIBB PHARMA COMPANY | 2003-01-07 | — | — | US | disclosed |
| EP-1222176-A1 | AMINO LACTAM SULFONAMIDES AS INHIBITORS OF A$g(b) PROTEIN PRODUCTION | Bristol-Myers Squibb Pharma Company (US) | 2002-07-17 | — | — | EP | disclosed |
| EP-1218377-A1 | AMINO LACTAM SULFONAMIDES AS INHIBITORS OF A$g(b) PROTEIN PRODUCTION | Bristol-Myers Squibb Pharma Company (US) | 2002-07-03 | — | — | EP | disclosed |
| WO-2001027091-A1 | AMINO LACTAM SULFONAMIDES AS INHIBITORS OF Aβ PROTEIN PRODUCTION | DU PONT PHARMACEUTICALS COMPANY (US) | 2001-04-19 | — | — | WO | disclosed |
| WO-2001027108-A1 | AMINO LACTAM SULFONAMIDES AS INHIBITORS OF Aβ PROTEIN PRODUCTION | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2001-04-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030130251-A1 | Amino lactam sulfonamides as inhibitors of A-beta protein production | APP, APH1A, BACE1 | MMP13 3485/4885MMP1 2125/4885USP2 1089/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.